Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søg Study Connect

Recruiting

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome - IM039-004

Opdateret: 30 juni, 2023   |   ClinicalTrials.gov

Udskriftsvenligt sammendrag

OVERVEJER DU DETTE FORSØG?
Udskriv denne side og forsøgsvejledningen som en hjælp til at tale med din læge.
Brug vejledningen til forsøgsdeltagere for at finde rundt i processen for deltagelse i et klinisk forsøg. Forstå de vigtigste faktorer, der skal overvejes, før du beslutter dig, og find spørgsmål, du kan stille dit sundhedsteam.

Forsøgsdetaljer

  • Phase 1

    Fase

  • Køn

  • 18-75

    Aldersinterval

  • 2

    Beliggenhed(er)

  • Recruiting

Behandlingsmuligheder

Forsøgsgrene
TILDELT INTERVENTION
Experimental: Part A SAD Dose 1
Biological: BMS-986325
Experimental: Part A SAD Dose 2
Other: Placebo
Experimental: Part A SAD Dose 3
Biological: BMS-986325
Experimental: Part A SAD Dose 4
Other: Placebo
Experimental: Part A SAD Dose 5
Biological: BMS-986325
Experimental: Part A SAD Dose 6
Other: Placebo

Primære egnethedskriterier

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - BMI: 18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening - Must agree to follow specific methods of contraception, if applicable Healthy Participants (Part A and Part B) - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations - Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening Participants with Sjögren's Syndrome (Part C) - Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS) - Seropositive for anti-Sjögren's syndrome antigen A antibody - Males and females, ages 18, or local age of majority, to 65 years, inclusive at screening Exclusion Criteria: - Woman who are pregnant or breastfeeding - Inability to tolerate venipuncture and/or inadequate venous access Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness - Any other significant medical, psychiatric, and/or social reason as determined by the investigator Participants with Sjögren's Syndrome (Part C) - Systemic immune-mediated disease other than pSS, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjögren's syndrome) - Another immune-mediated disease or inflammatory condition that could interfere with assessment of response of pSS to therapy (e.g., immunoglobulin G4 (IgG4)-related disease, systemic sclerosis, inflammatory bowel disease, gout) - Any other medical condition associated with sicca syndrome (e.g., history of head and neck radiation treatment, diabetes mellitus, sarcoidosis, chronic graft-versus host disease), participants with sicca symptoms secondary to ongoing medication use based on the investigator's assessment Other protocol-defined inclusion/exclusion criteria apply

Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information

466-DK-2200001